Stocks and Investing
Stocks and Investing
Thu, February 22, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (AUPH) at Strong Buy with Decreased Target to $13 on, Feb 22nd, 2024
Ed Arce of HC Wainwright & Co., Maintained "Aurinia Pharmaceuticals Inc." (AUPH) at Strong Buy with Decreased Target from $15 to $13 on, Feb 22nd, 2024.
Ed has made no other calls on AUPH in the last 4 months.
There is 1 other peer that has a rating on AUPH. Out of the 1 peers that are also analyzing AUPH, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Douglas Miehm of "RBC Capital" Maintained at Buy with Decreased Target to $8 on, Friday, February 16th, 2024
Contributing Sources